NASDAQ:ARNA Arena Pharmaceuticals (ARNA) Stock Price, News & Analysis → After Conviction, More Bad News for Trump (From Paradigm Press) (Ad) Free ARNA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$99.99▼$99.9950-Day Range$93.13▼$99.9952-Week Range$45.50▼$100.00Volume107 shsAverage Volume1.56 million shsMarket Capitalization$6.17 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Arena Pharmaceuticals alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Arena Pharmaceuticals Stock (NASDAQ:ARNA)Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.Read More Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… ARNA Stock News HeadlinesAugust 31, 2023 | uk.investing.comArwana Citramulia Tbk (ARNA)August 21, 2023 | foxnews.comMLS club places Bruce Arena on leave over probe into 'allegations of insensitive and inappropriate remarks'May 23, 2023 | bizjournals.comRNA startup launches with $300M, Merck partnershipMay 23, 2023 | seekingalpha.comLongboard Pharmaceuticals: Undervalued Arena Spin-Out Has 2 Data Catalysts Due In 2023May 6, 2023 | cnbc.comPfizer earnings and revenue top expectations despite Covid vaccine sales declineApril 25, 2023 | health.usnews.comArna L. DavidsonApril 12, 2023 | foxnews.comPortland, Maine, reopens basketball arena to migrantsMarch 17, 2023 | forbes.comIs Pfizer Stock Undervalued At $40?February 9, 2023 | benzinga.comArna Marketing Group Continues Investing in State-of-the-art Canon Inkjet Technology to Deliver "The Arna Advantage"February 8, 2023 | finance.yahoo.comArna Marketing Group Continues Investing in State-of-the-art Canon Inkjet Technology to Deliver “The Arna Advantage”February 6, 2023 | msn.comA DNA protein may be responsible for causing cancerous ‘stress balls’ in the body: U of S researchAugust 23, 2022 | thestreet.comObesity Drugs: The Road to PerditionAugust 9, 2022 | baystreet.caPfizer to Buy Global Blood TherapeuticsAugust 4, 2022 | forbes.comShould You Buy Pfizer Stock After An Upbeat Q2?June 29, 2022 | forbes.comShould You Buy, Sell, Or Hold Pfizer Stock At $52?May 3, 2022 | theglobeandmail.com7 Biotech Stocks With Key Catalysts in MarchMarch 10, 2022 | seekingalpha.comPfizer confirms HSR waiting period for Arena Pharmaceuticals deal expiredMarch 7, 2022 | seekingalpha.comArena Pharma gains after report Pfizer deal will clear without HSR second requestFebruary 25, 2022 | seekingalpha.comArena Pharmaceuticals GAAP EPS of -$2.54 misses by $0.31February 24, 2022 | msn.comArena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in FocusFebruary 23, 2022 | uk.finance.yahoo.comSFO opens criminal probe into collapse of Arena TelevisionFebruary 23, 2022 | finance.yahoo.comArena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program UpdatesFebruary 9, 2022 | finance.yahoo.comArena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23February 9, 2022 | benzinga.comHC Wainwright & Co. Downgrades Arena Pharmaceuticals to Neutral, Lowers Price Target to $100February 9, 2022 | markets.businessinsider.comExpert Ratings For Arena PharmaceuticalsSee More Headlines Receive ARNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today6/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ARNA CUSIP04004710 CIK1080709 Webwww.arenapharm.com Phone(858) 453-7200Fax858-453-7210Employees448Year Founded1977Profitability EPS (Most Recent Fiscal Year)($10.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-616,430,000.00 Net MarginsN/A Pretax Margin-1,141,542.63% Return on Equity-69.83% Return on Assets-62.35% Debt Debt-to-Equity Ratio0.05 Current Ratio8.59 Quick Ratio8.59 Sales & Book Value Annual Sales$50,000.00 Price / Sales123,305.67 Cash FlowN/A Price / Cash FlowN/A Book Value$10.94 per share Price / Book9.14Miscellaneous Outstanding Shares61,659,000Free Float60,173,000Market Cap$6.17 billion OptionableOptionable Beta0.55 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Amit D. Munshi M.B.A. (Age 54)Pres & CEO Comp: $1.22MMs. Laurie D. Stelzer (Age 54)Exec. VP & CFO Comp: $630.76kMr. Vincent E. Aurentz (Age 54)Exec. VP & Chief Bus. Officer Comp: $692.82kDr. Christopher H. Cabell FACCM.D., MHS, AdvisorMr. Robert Lisicki (Age 54)Exec. VP & Chief Commercial Officer Comp: $686.63kDr. Douglas A. Bakan Ph.D.Exec. VP of Technical OperationsDr. Lamine Mbow Ph.D.Sr. VP & Chief Scientific OfficerMegan E. KnightDirector of Investor RelationsPatrick MalloyVP of Investor Relations & Corp. CommunicationsMr. Michael E. Paolucci (Age 62)Exec. VP of HR More ExecutivesKey CompetitorsLegend BiotechNASDAQ:LEGNApellis PharmaceuticalsNASDAQ:APLSInsmedNASDAQ:INSMChemoCentryxNASDAQ:CCXIPrincipia BiopharmaNASDAQ:PRNBView All Competitors ARNA Stock Analysis - Frequently Asked Questions How were Arena Pharmaceuticals' earnings last quarter? Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.53) by $0.68. During the same period in the prior year, the firm earned ($1.69) EPS. When did Arena Pharmaceuticals' stock split? Shares of Arena Pharmaceuticals reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO? 16 employees have rated Arena Pharmaceuticals Chief Executive Officer Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among the company's employees. What other stocks do shareholders of Arena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T). This page (NASDAQ:ARNA) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arena Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.